Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New Investment in Biogen Inc. $BIIB

Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 18,873 shares of the biotechnology company’s stock, valued at approximately $3,321,000.

A number of other large investors also recently made changes to their positions in BIIB. Orion Porfolio Solutions LLC lifted its stake in shares of Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after purchasing an additional 509,809 shares during the period. Caisse de depot et placement du Quebec lifted its stake in shares of Biogen by 718.2% during the 3rd quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock worth $79,741,000 after purchasing an additional 499,676 shares during the period. AQR Capital Management LLC lifted its stake in shares of Biogen by 30.7% during the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock worth $248,809,000 after purchasing an additional 418,776 shares during the period. Alyeska Investment Group L.P. lifted its stake in shares of Biogen by 66.1% during the 3rd quarter. Alyeska Investment Group L.P. now owns 845,277 shares of the biotechnology company’s stock worth $118,406,000 after purchasing an additional 336,504 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Biogen by 425.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 348,404 shares of the biotechnology company’s stock worth $48,804,000 after purchasing an additional 282,084 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BIIB. Argus raised Biogen to a “hold” rating in a research note on Thursday, April 9th. Barclays initiated coverage on Biogen in a report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 target price on the stock. Guggenheim boosted their price target on Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. HC Wainwright reissued a “buy” rating on shares of Biogen in a research report on Thursday, May 14th. Finally, Wells Fargo & Company boosted their price target on Biogen from $190.00 to $200.00 and gave the company an “equal weight” rating in a research report on Sunday, February 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $215.62.

Biogen Price Performance

BIIB stock opened at $187.80 on Thursday. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97. The company has a market cap of $27.73 billion, a PE ratio of 20.15, a price-to-earnings-growth ratio of 1.68 and a beta of 0.19. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The stock has a 50-day moving average price of $185.39 and a two-hundred day moving average price of $180.41.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the prior year, the firm earned $3.02 EPS. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, research analysts predict that Biogen Inc. will post 14.18 EPS for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.